OBJECTIVE: To compare the serum GRP78 levels in subjects with CAM and COVID-19 controls without mucormycosis.
METHODS: We performed a hospital-based, case-control study between 1 April 2021 and 31 May 2021.
METHODS: We enrolled 24 subjects each of CAM and COVID-19 subjects without mucormycosis. We also measured serum GRP78 levels in ten healthy controls.
METHODS: The primary exposure studied was serum GRP78 concentration, estimated using a commercially available ELISA kit in stored serum samples.
RESULTS: We found the mean ± standard deviation (SD) serum GRP78 levels significantly higher (p = 0.0001) among the CAM (374.3 ± 127.3 pg/mL) than the COVID-19 (246.4 ± 67.0 pg/mL) controls. The proportion of subjects with an abnormal GRP78 level (> mean [184.8 pg/mL] plus two SD [23.2 pg/mL] of GRP78 from healthy participants) was 87.5% and 45.8% in the CAM group and COVID-19 controls, respectively. Serum GRP78 level was independently associated with CAM (odds ratio 1.011; 95% confidence interval [1.002-1.019]) after adjusting for diabetes mellitus and hypoxemia during acute COVID-19.
CONCLUSIONS: Serum GRP78 levels were significantly higher in CAM than in COVID-19 controls. Further studies are required to the role of GRP78 in the pathogenesis of CAM.
目的:比较没有毛霉菌病的CAM和COVID-19对照组的血清GRP78水平。
方法:我们以医院为基础,2021年4月1日至2021年5月31日的病例对照研究。
方法:我们招募了24名没有毛霉菌病的CAM和COVID-19受试者。我们还测量了十个健康对照的血清GRP78水平。
方法:研究的主要暴露是血清GRP78浓度,使用市售ELISA试剂盒在储存的血清样品中进行估计。
结果:我们发现,与COVID-19(246.4±67.0pg/mL)对照相比,CAM(374.3±127.3pg/mL)中的血清GRP78水平(p=0.0001)明显更高(p=0.0001)。在CAM组和COVID-19对照组中,GRP78水平异常(>平均[184.8pg/mL]加上健康参与者的GRP78的两个SD[23.2pg/mL])的受试者比例为87.5%和45.8%,分别。在校正急性COVID-19期间的糖尿病和低氧血症后,血清GRP78水平与CAM(比值比1.011;95%置信区间[1.002-1.019])独立相关。
结论:CAM组血清GRP78水平明显高于COVID-19对照组。GRP78在CAM发病机制中的作用有待进一步研究。